Leonard, J., Ladha, A., Faramand, R., Roloff, G., Valtis, Y., Tan, V., … Aldoss, I. (2025). KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel). In Blood (Vol. 146, pp. 3365–3365). American Society of Hematology. https://doi.org/10.1182/blood-2025-3365

Leonard, Jessica, Abdullah Ladha, Rawan Faramand, Gregory Roloff, Yannis Valtis, Virginia Tan, Katharine Miller, et al. “KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel).” In Blood, 146:3365–3365. American Society of Hematology, 2025. https://doi.org/10.1182/blood-2025-3365.

Leonard J, Ladha A, Faramand R, Roloff G, Valtis Y, Tan V, et al. KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel). In: Blood. American Society of Hematology; 2025. p. 3365–3365.

Leonard, Jessica, et al. “KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel).” Blood, vol. 146, no. Supplement 1, American Society of Hematology, 2025, pp. 3365–3365. Crossref, doi:10.1182/blood-2025-3365.

Leonard J, Ladha A, Faramand R, Roloff G, Valtis Y, Tan V, Miller K, Zhang A, Grunwald M, Kota V, Boccucci J, Ulrickson M, Al-Darobi A, Hill L, Muhsen I, Sasine J, Advani A, Sandhu K, Reshef R, Luskin M, Chen E, Lin C, Cassaday R, Kopmar N, Solh M, Lee C, Odstrcil Bobillo S, Tsai S, O’Connor T, Hilal T, Park J, Vasu S, Bezerra E, O’Dwyer K, Moore J, Wang E, McCauley R, Majhail N, Ramakrishnan A, Mountjoy L, Malik S, Battiwalla M, Shaughnessy P, Mathews J, Srinagesh H, Sutherland K, Jamy O, Mohty R, Kumaran M, Hoeg R, Oliai C, Lill G, Stock W, Schwartz M, Othman T, Koura D, Dykes K, Logan A, Daunov M, Byrd K, Yalniz F, Bachanova V, Tracy S, Grover P, Connor M, Yaghmour G, Irizarry Gatell V, Jackson C, Oluwole O, Dholaria B, Frey N, Muffly L, Shah B, Aldoss I. KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel). Blood. American Society of Hematology; 2025. p. 3365–3365.